RxDoctor Payments Data

Henry Khin, MD

Psychiatry · Arcadia, CANPI 1871639682

Payments from drug & device makers

$5,713in general payments, 2019–2025

Across 368 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$767
  • Teva Pharmaceuticals USA, Inc.$705
  • Supernus Pharmaceuticals, Inc.$370
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$284
  • Lundbeck LLC$258
  • plus $777 from 10 others

What the payments were for

  • Food & beverage$5,51597%
  • Education$1983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,713 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$393,052
Medicare patients
294
Services billed
3,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate166$573,392
AristadaAripiprazole Lauroxil44$130,075
Austedo XrDeutetrabenazine11$79,988
FanaptIloperidone21$74,152
AustedoDeutetrabenazine14$60,829
Abilify MaintenaAripiprazole20$52,573
VraylarCariprazine Hcl21$29,024
Quetiapine Fumarate1,407$20,186
Aripiprazole530$20,006
TrintellixVortioxetine Hydrobromide35$19,733
Paliperidone ErPaliperidone94$19,637
LybalviOlanzapine/Samidorphan Malate12$18,174
RexultiBrexpiprazole12$16,889
Aripiprazole OdtAripiprazole43$14,884
Trazodone Hcl1,354$13,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$767$573,392166 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$705$140,81625 claims
AbbVieVraylar$2,554$29,02421 claims
Almatica Pharma LLCSertraline Hcl$130$3,831581 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →